Table. Baseline Characteristics in Patients With No Events, 1 Event, or 2 or More Events.
| Characteristic | No. (%) | |||||
|---|---|---|---|---|---|---|
| Monotherapy | Combination therapy | |||||
| No eventsa | 1 Eventa | ≥2 Eventsa | No eventsa | 1 Eventa | ≥2 Eventsa | |
| No. | 996 | 89 | 22 | 947 | 119 | 42 |
| Age, mean (SD), y | 74.0 (8.3) | 75.9 (8.0) | 78.9 (7.4) | 73.9 (8.1) | 76.1 (8.6) | 78.6 (8.0) |
| ≥75 y | 512 (51.4) | 54 (60.7) | 16 (72.7) | 476 (50.3) | 72 (60.5) | 33 (78.6) |
| Male sex | 795 (79.8) | 66 (74.2) | 14 (63.6) | 748 (79.0) | 95 (79.8) | 33 (78.6) |
| Female sex | 201 (20.2) | 23 (25.8) | 8 (36.4) | 199 (21.0) | 24 (20.2) | 9 (21.4) |
| BMI, mean (SD)b | 24.6 (3.7) | 23.4 (3.7) | 24.1 (3.5) | 24.5 (3.7) | 24.8 (4.2) | 23.0 (3.3) |
| Type of AF | ||||||
| Paroxysmal | 546 (54.8) | 40 (44.9) | 10 (45.5) | 517 (54.6) | 43 (36.1) | 20 (47.6) |
| Persistent | 147 (14.8) | 13 (14.6) | 4 (18.2) | 142 (15.0) | 24 (20.2) | 9 (21.4) |
| Permanent | 303 (30.4) | 36 (40.4) | 8 (36.4) | 288 (30.4) | 52 (43.7) | 13 (31.0) |
| Hypertension | 854 (85.7) | 76 (85.4) | 17 (77.3) | 812 (85.7) | 99 (83.2) | 33 (78.6) |
| Diabetes | 408 (41.0) | 44 (49.4) | 9 (40.9) | 380 (40.1) | 63 (52.9) | 23 (54.8) |
| Dyslipidemia | 697 (70.0) | 69 (77.5) | 15 (68.2) | 647 (68.3) | 83 (69.7) | 27 (64.3) |
| Angina | 609 (61.1) | 60 (67.4) | 18 (81.8) | 608 (64.2) | 84 (70.6) | 31 (73.8) |
| Heart failure | 337 (33.8) | 42 (47.2) | 10 (45.5) | 315 (33.3) | 62 (52.1) | 22 (52.4) |
| Bleeding diathesis | 15 (1.5) | 3 (3.4) | 1 (4.5) | 10 (1.1) | 2 (1.7) | 1 (2.4) |
| Previous stroke | 131 (13.2) | 15 (16.9) | 2 (9.1) | 145 (15.3) | 20 (16.8) | 10 (23.8) |
| Previous myocardial infarction | 345 (34.6) | 35 (39.3) | 4 (18.2) | 332 (35.1) | 48 (40.3) | 13 (31.0) |
| Previous peripheral arterial disease | 58 (5.8) | 8 (9.0) | 1 (4.5) | 56 (5.9) | 12 (10.1) | 4 (9.5) |
| Previous PCI | 704 (70.7) | 64 (71.9) | 13 (59.1) | 662 (69.9) | 89 (74.8) | 32 (76.2) |
| Type of stent, No./total No. (%) | ||||||
| Bare metal | 155/651 (23.8) | 15/59 (25.4) | 1/13 (7.7) | 140/610 (23.0) | 24/79 (30.4) | 7/32 (21.9) |
| Drug-eluting | 451/651 (69.3) | 39/59 (66.1) | 10/13 (76.9) | 408/610 (66.9) | 50/79 (63.3) | 19/32 (59.4) |
| Both types | 14/651 (2.2) | 3/59 (5.1) | 2/13 (15.4) | 30/610 (4.9) | 2/79 (2.5) | 4/32 (12.5) |
| Unknown | 31/651 (4.8) | 2/59 (3.4) | 0/13 (0) | 32/610 (5.2) | 3/79 (3.8) | 2/32 (6.3) |
| Previous CABG | 111 (11.1) | 13 (14.6) | 1 (4.5) | 107 (11.3) | 15 (12.6) | 5 (11.9) |
| Initial dose of rivaroxaban | ||||||
| 10 mg/d | 436 (43.8) | 47 (52.8) | 14 (63.6) | 426 (45.0) | 63 (52.9) | 24 (57.1) |
| 15 mg/d | 551 (55.3) | 40 (44.9) | 8 (36.4) | 512 (54.1) | 55 (46.2) | 18 (42.9) |
| CHADS2 score, median (IQR) | 2 (2-3) | 3 (2-3) | 3 (2-3) | 2 (2-3) | 3 (2-4) | 3 (2-4) |
| CHA2DS2-VASc score, median (IQR) | 4 (3-5) | 4 (3-6) | 4 (4-5) | 4 (3-5) | 4 (3-6) | 5 (4-6) |
| HAS-BLED, median (IQR) | 2 (2-3) | 2 (2-3) | 2 (1-3) | 2 (2-3) | 2 (2-3) | 2 (2-3) |
| CrCl | ||||||
| Mean (SD), mL/min | 63.9 (25.9) | 53.5 (22.2) | 51.3 (21.7) | 63.0 (24.3) | 55.2 (21.3) | 51.3 (19.4) |
| Distribution, No./total No. (%) | ||||||
| <30 mL/min | 42/946 (4.4) | 9/85 (10.6) | 3/22 (13.6) | 44/886 (5.0) | 12/112 (10.7) | 4/41 (9.8) |
| 30-<50 mL/min | 254/946 (26.8) | 36/85 (42.4) | 10/22 (45.5) | 241/886 (27.2) | 34/112 (30.4) | 18/41 (43.9) |
| ≥50 mL/min | 650/946 (68.7) | 40/85 (47.1) | 9/22 (40.9) | 601/886 (67.8) | 66/112 (58.9) | 19/41 (46.3) |
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; CHA2DS2-VASc, congestive heart failure, hypertension, age >75, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female sex score; CHADS2, congestive heart failure, hypertension, age older than 75 years, diabetes mellitus, and prior stroke or transient ischemic attack score; CrCl, creatinine clearance; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, elderly, drugs/alcohol concomitant score; PCI, percutaneous coronary intervention.
SI conversion factor: To convert creatinine clearance to milliliter per second per meter squared, multiply by 0.0167.
Categorized according to the number of major bleeding, hemorrhagic stroke, ischemic stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, and death from any cause.
Calculated as weight in kilograms divided by height in meters squared.